These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 2357118)

  • 1. Deferoxamine for aluminum toxicity in dialysis patients.
    Hernandez P; Johnson CA
    ANNA J; 1990 Jun; 17(3):224-8. PubMed ID: 2357118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aluminum-related osteomalacia in renal-failure patients.
    Vick KE; Johnson CA
    Clin Pharm; 1985; 4(4):434-9. PubMed ID: 3899471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aluminum intoxication in a child: treatment with intraperitoneal desferrioxamine.
    Warady BA; Ford DM; Gaston CE; Sedman AB; Huffer WE; Lum GM
    Pediatrics; 1986 Oct; 78(4):651-5. PubMed ID: 3763276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The chemistry of desferrioxamine chelation for aluminum overload in renal dialysis patients.
    Day JP; Ackrill P
    Ther Drug Monit; 1993 Dec; 15(6):598-601. PubMed ID: 8122301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Desferrioxamine in the treatment of aluminum overload.
    Ackrill P; Day JP
    Clin Nephrol; 1985; 24 Suppl 1():S94-7. PubMed ID: 3842106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Aluminum poisoning].
    Cervar M; Stavljenic A; Vukicević S
    Lijec Vjesn; 1989; 111(4-5):164-9. PubMed ID: 2671563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Encephalopathy in chronic renal failure responsive to deferoxamine therapy. Another manifestation of aluminum neurotoxicity.
    Sprague SM; Corwin HL; Wilson RS; Mayor GH; Tanner CM
    Arch Intern Med; 1986 Oct; 146(10):2063-4. PubMed ID: 3767553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intraperitoneal deferoxamine therapy for aluminum intoxication in a child undergoing continuous ambulatory peritoneal dialysis.
    Andreoli SP; Dunn D; DeMyer W; Sherrard DJ; Bergstein JM
    J Pediatr; 1985 Nov; 107(5):760-3. PubMed ID: 3932629
    [No Abstract]   [Full Text] [Related]  

  • 9. Aluminum and deferoxamine kinetics in CAPD.
    Mactier RA
    Adv Perit Dial; 1991; 7():26-9. PubMed ID: 1680440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Do serum aluminum levels reflect underlying skeletal aluminum accumulation and bone histology before or after chelation by deferoxamine?
    Hodsman AB; Hood SA; Brown P; Cordy PE
    J Lab Clin Med; 1985 Dec; 106(6):674-81. PubMed ID: 4067379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sucralfate-associated aluminum toxicity in a patient with renal failure: treatment with deferoxamine.
    Min DI; D'Elia JA
    Clin Pharm; 1992 Jul; 11(7):636-9. PubMed ID: 1617916
    [No Abstract]   [Full Text] [Related]  

  • 12. [Desferrioxamine treatment of osteomalacia caused by aluminum poisoning].
    Charhon SA; Chavassieux P; Chapuy MC; Accominotti M; Traeger J; Meunier PJ
    Presse Med; 1986 Jan; 15(2):55-9. PubMed ID: 2935857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recognition and management of aluminum intoxication in children.
    Tsuru N; Williams JL; Chan JC
    Int J Pediatr Nephrol; 1987; 8(3):177-86. PubMed ID: 3323095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Precipitation of dialysis dementia by deferoxamine treatment of aluminum-related bone disease.
    Sherrard DJ; Walker JV; Boykin JL
    Am J Kidney Dis; 1988 Aug; 12(2):126-30. PubMed ID: 3400633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Severe ocular toxicity of desferrioxamine in the hemodialyzed patient].
    Bournerias F; Monnier N; Dufier JL; Réveillaud RJ
    Nephrologie; 1987; 8(1):27-9. PubMed ID: 3587485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement of anemia with deferoxamine in hemodialysis patients with aluminum-induced bone disease.
    Tielemans C; Collart F; Wens R; Smeyers-Verbeeke J; van Hooff I; Dratwa M; Verbeelen D
    Clin Nephrol; 1985 Nov; 24(5):237-41. PubMed ID: 4075595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Irreversible ocular toxicity from single "challenge" dose of deferoxamine.
    Bene C; Manzler A; Bene D; Kranias G
    Clin Nephrol; 1989 Jan; 31(1):45-8. PubMed ID: 2783668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microcytic anemia in dialysis patients: reversible marker of aluminum toxicity.
    Swartz R; Dombrouski J; Burnatowska-Hledin M; Mayor G
    Am J Kidney Dis; 1987 Mar; 9(3):217-23. PubMed ID: 3826071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The causes, diagnosis and treatment of aluminum toxicity in patients with chronic renal failure undergoing dialysis].
    Wang G; Zhu P; Wang S
    Zhonghua Nei Ke Za Zhi; 1996 Jan; 35(1):36-40. PubMed ID: 9275645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Speech apraxia in dialysis-associated aluminum encephalopathy].
    Haug BA; Botsch G; Felgenhauer K
    Nervenarzt; 1991 Oct; 62(10):637-40. PubMed ID: 1749454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.